Cite
HARVARD Citation
Oregel, K. et al. (2016). Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. Expert review of anticancer therapy. 16 (3), pp. 279-283. [Online].